Aileron Therapeutics, Inc.
ALRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $126 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $63 |
| Gross Profit | $0 | $0 | $0 | $63 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $1,681 | $4,292 | $3,054 | $3,322 |
| G&A Expenses | $3,811 | $2,579 | $2,555 | $2,475 |
| SG&A Expenses | $3,811 | $2,579 | $2,555 | $2,475 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,492 | $6,871 | $5,609 | $5,797 |
| Operating Income | -$5,492 | -$6,871 | -$5,609 | -$42,797 |
| % Margin | – | – | – | -33,965.9% |
| Other Income/Exp. Net | -$89 | $49 | $108 | $1,816 |
| Pre-Tax Income | -$5,581 | -$6,822 | -$5,501 | -$40,981 |
| Tax Expense | $0 | $0 | $0 | $59 |
| Net Income | -$5,581 | -$6,822 | -$5,501 | -$40,981 |
| % Margin | – | – | – | -32,524.6% |
| EPS | -0.21 | -0.28 | -0.25 | -2.07 |
| % Growth | 25% | -12% | 87.9% | – |
| EPS Diluted | -0.21 | -0.28 | -0.25 | -2.07 |
| Weighted Avg Shares Out | 26,361 | 24 | 21,916 | 19,801 |
| Weighted Avg Shares Out Dil | 26,361 | 24 | 21,916 | 19,801 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$63 |
| EBITDA | -$5,581 | -$6,871 | -$5,609 | -$40,985 |
| % Margin | – | – | – | -32,527.8% |